Budget Impact Analysis of Switching to Rituximab’s Biosimilar in Rheumatology and Cancer in 13 Countries Within the Middle East and North Africa

INTRODUCTION: Biosimilars of monoclonal antibodies are being rapidly developed and approved by public health regulatory authorities worldwide. These biosimilars are expected to bring significant budgetary savings to national governments and consequently increase patients’ accessibility to biological...

Descripción completa

Detalles Bibliográficos
Autor principal: Almaaytah, Ammar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501981/
https://www.ncbi.nlm.nih.gov/pubmed/32982342
http://dx.doi.org/10.2147/CEOR.S265041

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7501981/
https://www.ncbi.nlm.nih.gov/pubmed/32982342
http://dx.doi.org/10.2147/CEOR.S265041

Ejemplares similares